BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Interest Income

Income earned on cash, deposits, and investments held by the company.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income growth accelerates

Q2 FY2026 interest income of $6.66M rose 70.8% year over year, ahead of the +36.0% change in trailing-twelve-month interest income. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +38.1% a year.

Context

  • Interest income amounted to 4.0% of revenue in FY2025, down 3.8 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +70.8% holds above the trailing-twelve-month pace of +36.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.66M+6.6% QoQ
Last fiscal yearDec 2025
$19.85M+15.1% YoY
LTMJun 2026
$23.48M+36.0% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+70.8%——
1 year+15.1%——
3-year CAGR+38.1%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
19.85M USD
Year-over-year change
+15.1%
4-year CAGR
+104.6%

Interest Income vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.0% is the 5th highest of 10, against a peer median of -7.8%.
  • Interest income amounts to 3.3% of revenue for BBIO, versus a peer median of 4.1%.
BBIO Competitors
Interest Income for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$4.68B USD+6281.3%+60.7%0.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$110.05M USD-7.8%+65.0%2.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$89.99M USD-11.7%+56.9%9.4%
ASNDAscendis Pharma A/SLTM Sep 2026€56.37M EUR+172.4%+25.6%4.7%
DNLIDenali Therapeutics Inc.LTM Jun 2026$28.36M USD-48.1%+42.7%786.9%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$24.17M USD-30.0%+31.2%3.6%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$23.48M USD+36.0%+38.1%3.3%
SRRKScholar Rock Holding CorporationLTM Sep 2026$14.65M USD+138.4%—2570.2%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$12.38M USD+77.1%+79.8%61.9%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$12.24M USD-12.1%+26.6%1.9%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding BBIO) —-7.8%+49.8%4.1%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue69.72M77.65M9.3M221.9M502.08M
Cost of Revenue3.11M3.43M2.45M3.88M28.27M
Gross Profit66.6M74.21M6.86M218.02M473.81M
Gross Margin95.5%95.6%73.7%98.3%94.4%
Research & Development451.02M399.46M455.71M506.46M477.54M
Selling, General & Admin192.21M143.19M150.59M288.93M555.14M
Operating Expenses643.23M586.42M614.23M811M1.04B
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
EBITDA(533.83M)(397.44M)(565.47M)(436.83M)(676.45M)
EBITDA Margin-765.7%-511.9%-6078.3%-196.9%-134.7%
Operating Income(576.63M)(512.2M)(607.37M)(592.97M)(569.09M)
Operating Margin-827.1%-659.6%-6528.8%-267.2%-113.3%
Interest Income1.13M7.54M18.04M17.25M19.85M
Interest Expense46.78M80.44M81.29M99.29M53.1M
Other Income / Expenses(9.82M)27.55M(45.88M)50.78M(165.9M)
Income Before Tax(586.45M)(484.65M)(653.25M)(542.19M)(734.99M)
Pre-Tax Margin-841.2%-624.2%-7021.9%-244.3%-146.4%
Income Tax Expense0001.15M555K
Net Income(562.54M)(481.18M)(643.2M)(535.76M)(729.31M)
Net Margin-806.9%-619.7%-6913.9%-241.4%-145.3%
EPS (Basic)(3.90)(3.35)(3.95)(2.88)(3.79)
EPS (Diluted)(3.90)(3.35)(3.95)(2.88)(3.79)
Weighted Avg Shares144.36M147.47M162.79M186.08M197.24M
Weighted Avg Shares (Diluted)144.36M147.47M162.79M186.08M197.24M

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.